Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit affecting millions of individuals globally. Effective clinical management requires a two-pronged strategy: arresting active inflammatory lesions to prevent tissue loss, and executing targeted scar revision procedures to restore the dermal extracellular matrix. Medical therapies reduce sebum, normalize keratinocyte desquamation, and suppress microbial triggers. Dermal scar revision utilizes energy-based devices, mechanical resurfacing, chemical exfoliation, and minor surgical release to stimulate collagen cross-linking and replace abnormal fibrotic tissue.

Acne and acne scar management employs a phased strategy tailored to disease activity and scar architecture. Active medical management includes topical retinoids (adapalene, tretinoin, trifarotene), benzoyl peroxide, topical or oral antibiotics (doxycycline, sarecycline), hormonal therapies (spironolactone, oral contraceptives), or oral isotretinoin. Procedural interventions for scar revision include chemical reconstruction of skin scars (CROSS technique using high-concentration trichloroacetic acid), microneedling (collagen induction therapy), fractional ablative laser resurfacing (CO2 or Erbium:YAG), vascular lasers (595-nm pulsed dye laser), subcision (blunt needle release of tethered fibrous bands), and soft tissue augmentation or punch excision.

Evidence-based dermatological therapies provide substantial clinical and psychological benefits supported by robust trial evidence:

• Significant lesion reduction: Standard systemic and topical regimens reduce inflammatory lesion counts by 50% to 80% within 12 weeks of initiation (AAD Guidelines 2024).
• Prevention of secondary scarring: Early, aggressive suppression of deep inflammatory nodules significantly lowers the incidence of irreversible dermal scarring.
• Dermal remodeling and scar depth reduction: Fractional energy devices and subcision demonstrate a 40% to 70% quantitative improvement in atrophic scar volume on clinical profilometry (EADV Guidelines 2023).
• Dyschromia resolution: Targeted chemical peels and vascular light therapies accelerate the clearance of post-inflammatory erythema and hyperpigmentation by enhancing cellular turnover and vascular coagulation.
• Improved health-related quality of life: Validated measures such as the Dermatology Life Quality Index (DLQI) consistently demonstrate meaningful psychological improvement following structured acne and scar management.

Recovery timelines vary depending on whether treatment involves medical maintenance, non-ablative procedures, or aggressive surgical and ablative scar revision. Superficial chemical peels and non-ablative lasers involve minimal downtime of 24 to 48 hours characterized by mild erythema (redness) and transient edema (swelling). Deep ablative laser resurfacing, high-intensity radiofrequency microneedling, and extensive subcision require 7 to 14 days of active healing, during which patients experience crusting, peeling, and skin re-epithelialization. Full dermal collagen maturation and final scar remodeling continue beneath intact epidermis for 3 to 6 months post-procedure.

Clinical interventions target both active cutaneous acne disorders and secondary persistent tissue alterations. Specific treated conditions include:

• Comedonal acne: Non-inflammatory open and closed microcomedones caused by follicular hyperkeratinization.
• Inflammatory papules and pustules: Superficially inflamed lesions mediated by Cutibacterium acnes proliferation and localized immune cascades.
• Nodulocystic acne: Deep, painful dermal lesions carrying high risk for structural skin damage and permanent scarring.
• Atrophic acne scars: Permanent dermal tissue loss categorized into icepick (narrow, deep), boxcar (sharply demarcated), and rolling (undulating, fibrous-tethered) scars.
• Hypertrophic and keloidal scars: Excessive collagen accumulation resulting from abnormal tissue healing, primarily over the jawline, chest, and back.
• Post-inflammatory hyperpigmentation (PIH) and erythema (PIE): Reactive macular dyschromia and vascular ectasia persisting following lesion resolution.

Pre-treatment evaluation includes a thorough clinical skin examination, Fitzpatrick skin phototype classification, assessment of active inflammation, and medical history review. Patients undergoing aggressive scar revision procedures must discontinue topical retinoids 3 to 7 days prior, avoid direct sun exposure, and adhere to strict broad-spectrum photoprotection. Patients with a history of herpes simplex virus (HSV) infection receive prophylactic oral antiviral medications starting 24 to 48 hours before invasive ablative procedures. Pre-treatment with topical tyrosinase inhibitors (hydroquinone or azelaic acid) may be indicated for higher Fitzpatrick phototypes (IV-VI) to reduce post-inflammatory hyperpigmentation risk.

Standard medical and procedural interventions carry recognized clinical risks. Common transient adverse effects include localized erythema, xerosis (dry skin), scaling, burning, and temporary post-inflammatory hyperpigmentation (PIH). Less common complications include secondary bacterial or viral infections (e.g., reactivation of herpes simplex), prolonged post-procedural erythema lasting over 3 months, contact dermatitis, and scarring exacerbation. Rare but severe complications include true keloid formation, permanent skin hypopigmentation, persistent hyperpigmentation refractory to topical therapy, systemic side effects from oral isotretinoin (teratogenicity, hypertriglyceridemia, mucocutaneous dryness), and corneal damage from improper laser safety protocols.

The clinical care pathway begins with a comprehensive dermatological assessment to classify acne severity using validated instruments like the Global Acne Grading System (GAGS) and evaluate scar architecture using the Goodman and Baron quantitative system. Patients first undergo medical stabilization using topical or systemic agents to eliminate active inflammatory papules, pustules, and nodules. Once active inflammation is controlled, a customized procedural plan is initiated, which may include laser resurfacing, chemical peels, microneedling, or subcision. Post-procedural care focuses on re-epithelialization, strict photoprotection, and long-term maintenance therapy to sustain clinical improvement and prevent relapse.